Details from Novartis’ failed cardiovascular trial offer ‘little silver lining’ for rivals
Novartis and Ionis reported that pelacarsen failed to reduce cardiovascular events in the HORIZON trial, despite lowering lipoprotein(a) levels. Analysts see a challenging path for Lp(a)-targeting therapies, including Amgen's olpasiran and Eli Lilly's lepodisiran. Novartis' stock was impacted, and analysts lowered success probabilities for competitors' drugs. The trial results raise questions about the viability of Lp(a) targeting in cardiovascular disease.
How this was made
The 30-second read
Why it matters
The data reshapes expectations for the entire Lp(a) therapeutic class, prompting analysts to downgrade peer programs and potentially trigger sell‑offs in related biotech stocks.
Market read
First disclosure of a pivotal cardiovascular trial failure; immediate impact on multiple large‑cap pharma stocks and the broader Lp(a) drug space.
What to watch
The FDA investigation into Novartis' Zolgensma tumors may compound risk, but also distract from the Lp(a) failure.
Background
The HORIZON Phase 3 trial of pelacarsen, an antisense oligonucleotide targeting Lp(a), enrolled 8,300 patients over seven years and failed to reduce major adverse cardiovascular events.
Ticker impact
Novartis' pelacarsen failed to meet primary endpoint in the Phase 3 HORIZON trial, revealing no MACE benefit.
likely downward pressure as investors reassess Lp(a) program
First disclosure of a pivotal Phase 3 failure for a major cardiovascular asset.
Ionis co‑developed pelacarsen with Novartis; the trial failure directly impacts its antisense pipeline.
downward pressure from loss of a key partnership milestone
Partner's failure removes near‑term commercial upside for Ionis.
Amgen's Lp(a) siRNA candidate olpasiran saw its success probability cut after the Novartis data.
moderate downside as market re‑prices reduced odds
Peer impact from trial data, but no direct product failure.
Eli Lilly's Lp(a) siRNA lepodisiran is similarly affected by the negative trial readout.
moderate downside pending further data releases
Peer effect; no direct trial data on Lilly's asset yet.
Market effects
Cardiovascular drug pipeline valuations may be compressed; Lp(a) targeting strategies face heightened scrutiny.
European biotech indices could dip as several firms face setbacks.
Large‑cap pharma stocks worldwide may see short‑term volatility.
Counterpoint
If the trial shows high discontinuation rates, a subset of responders could still support a later indication, offering upside on a rebound.
Key entities
- CompanyNovartis
Pharma giant co‑developing pelacarsen.
- CompanyIonis Pharmaceuticals
Antisense partner on pelacarsen.
- CompanyAmgen
Developer of olpasiran, an Lp(a) siRNA.
- CompanyEli Lilly
Developer of lepodisiran, an Lp(a) siRNA.
